Market closed

Nuvation Bio/$NUVB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Nuvation Bio

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Ticker

$NUVB
Sector
Health Care

Trading on

NYSE

Industry

Pharmaceuticals
Headquarters
New York, United States

Employees

203
Website
www.nuvationbio.com

Nuvation Bio Metrics

BasicAdvanced
$885M
Market cap
-
P/E ratio
-$2.23
EPS
1.36
Beta
-
Dividend rate
$885M
1.36
$4.16
$1.33
2.4M
9.57
9.374
0.196
2.226
-533.52%
-13.98%
-95.54%
290.961
1.76
1.77
-6.333
487.59%
73.59%

What the Analysts think about Nuvation Bio

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.

Nuvation Bio Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Nuvation Bio Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Nuvation Bio News

AllArticlesVideos
Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NUVB

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Nuvation Bio stock?

Nuvation Bio (NUVB) has a market cap of $885M as of December 13, 2024.

What is the P/E ratio for Nuvation Bio stock?

The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of December 13, 2024.

Does Nuvation Bio stock pay dividends?

No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of December 13, 2024.

When is the next Nuvation Bio dividend payment date?

Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.

What is the beta indicator for Nuvation Bio?

Nuvation Bio (NUVB) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.